PT-141 Ireland: what Irish law says about bremelanotide, why it is not an approved medicine there, and what researchers and patients should know before buying.
PT-141 (bremelanotide) is not an authorized medicine in Ireland. The Health Products Regulatory Authority has never approved a bremelanotide product for the Irish market, and the European Medicines Agency has not granted the drug a marketing authorization anywhere in the EU, so no Irish pharmacy can dispense it and no standard Irish prescription can be filled for it. Anything sold as PT-141 to buyers in Ireland comes through unregulated channels, with the legal and safety problems that follow.
What PT-141 Is and What It Is Approved For
PT-141 is a synthetic peptide that acts as a melanocortin receptor agonist. It works mainly on MC4R receptors in the central nervous system, which is why it is often described as a desire drug rather than a blood-flow drug. It is not testosterone, not a hormone, and not a PDE5 inhibitor like sildenafil or tadalafil.
The only approved product is Vyleesi, cleared by the FDA in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide is a prescription-only medicine in the United States and has no approved use in men.
PT-141 in Ireland: The Regulatory Position
Irish and EU rules require a medicine to hold a marketing authorization before it can be sold or supplied. Bremelanotide does not. In practice that means:
- No Irish pharmacy can legally stock or sell PT-141.
- A standard prescription cannot be dispensed for it.
- Supplying it to another person, including selling vials through a website or social media, is generally an offence under medicinal product law.
- A doctor may apply for named-patient access to an unapproved medicine in narrow cases, but that is a case-by-case clinical route, not a way to source the peptide for personal use.
Personal importation is restricted as well. Irish customs routinely intercept parcels of unapproved injectable peptides, and the buyer has no way to verify what is inside the vial.
| Factor | Ireland / EU | United States |
|---|---|---|
| Regulatory status | Not authorized by the HPRA or EMA | FDA-approved as Vyleesi (2019) |
| Legal supply | No pharmacy supply; supply to others is generally an offence | Prescription only |
| Approved indication | None | Acquired, generalized HSDD in premenopausal women |
| Approved dose | None | 1.75 mg subcutaneous autoinjector |
| Import rules | Unapproved medicines are restricted and frequently seized | Applies to domestic supply only |
Forms, Dosing, and Timing
The approved injectable
Vyleesi is a single-use subcutaneous autoinjector that delivers 1.75 mg of bremelanotide, usually into the thigh or abdomen. The approved pt-141 dosage is one injection at least 45 minutes before anticipated sexual activity, never more than once in 24 hours, and no more than eight times a month.
Nasal spray and research powder
The earliest clinical work used an intranasal formulation, but development stopped after higher doses produced dose-dependent increases in blood pressure. Today, pt-141 nasal spray is sold online as a grey-market item that has never been evaluated by any regulator.
Lyophilized powder labeled “for research use only” is the other common format. It is not made to pharmaceutical standards, and purity and sterility vary significantly between vendors.
Timing
Many people ask “how long does pt-141 last.” Bremelanotide has a plasma half-life of roughly 2.7 hours, so effects usually begin within 45 to 60 minutes of an injection and typically fade over a few hours.
| Format | Regulatory status | Typical researched dose | Key concern |
|---|---|---|---|
| Subcutaneous autoinjector (Vyleesi) | FDA-approved | 1.75 mg | Nausea, transient blood pressure rise |
| Nasal spray | Never approved; development stopped | 10–20 mg in older trials | Dose-dependent blood pressure increases |
| Lyophilized research powder | Not a medicine at all | Not established | Purity, sterility, and dosing accuracy unverified |
What Research Shows About Effectiveness
Two Phase 3 trials in premenopausal women with HSDD found modest but measurable improvements in desire scores and in the number of satisfying sexual events compared with placebo. The benefit was real but small, and a meaningful share of participants saw little change.
Use in men is off-label and investigational. Small studies of pt-141 for men with erectile dysfunction showed some signal, particularly in men who did not respond to PDE5 inhibitors, but the evidence is far too thin to call it an established treatment. Likewise, pt-141 dosage for women above the approved 1.75 mg injection is not supported by data, and higher doses mainly increase nausea.
Side Effects and Safety
Nausea is the most frequently reported side effect, affecting roughly 40% of participants in trials. Flushing, headache, vomiting, and injection-site reactions are also common. Bremelanotide can produce temporary increases in blood pressure and heart rate after a dose.
- It is contraindicated for people with uncontrolled high blood pressure or known cardiovascular disease.
- Focal hyperpigmentation, including darkening of the skin and gums, has been reported, particularly with frequent use.
- It has not been studied in pregnancy or breastfeeding and is not recommended in either case.
- Bremelanotide may interact with other medicines that affect blood pressure.
Anyone weighing PT-141 should speak with a physician first. Unapproved peptide injections bypass the screening that would normally catch cardiovascular risk.
Buying PT-141 From Ireland: What to Watch For
With no authorized Irish supply, buyers usually end up on overseas research chemical sites or social media marketplaces. Common risks include:
- Unknown purity. Independent lab testing is optional for these sellers and rarely published.
- Broken cold chain. Peptides degrade when shipped without temperature control.
- Customs seizure. Intercepted parcels are destroyed, and the recipient may be contacted.
- No clinical oversight. Nobody screens for hypertension, heart disease, or drug interactions.
- Dosing errors. A mislabeled vial or an unclear reconstitution step can deliver far more than intended.
A safer route is to talk to a GP or sexual medicine specialist about approved options in Ireland, which can include therapy, hormone evaluation, and licensed medications for sexual dysfunction.
Bottom Line
PT-141 is not an approved medicine in Ireland, and there is no legal retail supply. Bremelanotide holds an FDA approval in the United States as Vyleesi for premenopausal women with HSDD, and nowhere else. The peptide sold under the PT-141 name online is unregulated, unverified, and carries genuine cardiovascular and legal risk.
Frequently Asked Questions
Is PT-141 legal in Ireland?
No. PT-141 (bremelanotide) holds no marketing authorization from the HPRA or the European Medicines Agency, so it cannot legally be sold or dispensed in Ireland. Supplying it to another person is generally an offence, and personal imports of unapproved medicines are restricted and often seized.
Can I get PT-141 on prescription in Ireland?
Not through a normal pharmacy prescription, because no bremelanotide product is authorized in Ireland. A doctor could in theory seek named-patient access to an unapproved medicine for a specific clinical reason, but that route is rare and is not designed for routine personal supply.
How long does PT-141 last?
Bremelanotide has a plasma half-life of about 2.7 hours. Effects typically start within 45 to 60 minutes of injection and generally ease over a few hours, which is why the FDA label limits dosing to once every 24 hours and no more than eight doses per month.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.